<DOC>
	<DOCNO>NCT00312195</DOCNO>
	<brief_summary>The objective study demonstrate effectiveness tolerability buprenorphine transdermal system ( 5 , 10 20 ) comparison match placebo transdermal system subject chronic nonmalignant pain syndrome currently control oral opioids . The double-blind treatment intervention duration 2 week time supplemental analgesic medication ( acetaminophen ) provide subject addition study drug .</brief_summary>
	<brief_title>Safety Efficacy Buprenorphine Transdermal System ( BTDS ) Subjects With Chronic Nonmalignant Pain</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>At least 2 month 's history nonmalignant pain , currently stable pain control opioid therapy . Good , good excellent pain control current opioid therapy . Willing able use telephone interactive voice response service . Currently receive daily morphine oxycodone monotherapy . Scheduled surgery disease site ( eg , major joint replacement surgery ) , major surgery , would fall within study period . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Chronic pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
	<keyword>Butransâ„¢ [ BTDS ]</keyword>
</DOC>